EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN BIOMIMETIC PHARMACEUTICALS, INC. AND ZYMOGENETICS, INC.Exclusive Patent License Agreement • May 10th, 2006 • Biomimetic Therapeutics, Inc. • Surgical & medical instruments & apparatus • Washington
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • June 12th, 2017 • Therapeutic Solutions International, Inc. • Surgical & medical instruments & apparatus • California
This Exclusive Patent License Agreement (the “Agreement” and/or “EPLA”) is made and entered into by and between Therapeutic Solutions International, Inc., a corporation organized under Nevada law (hereinafter the “Licensor”), having its principle office at 4093 Oceanside Blvd., Suite B, Oceanside CA, 92056, and Emvolio, Inc., a corporation organized under the laws of Delaware (hereinafter the “Licensee”), its principle office being located in Oceanside, California. Licensor and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” The Parties agree as follows:
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM AND MIRAGEN THERAPEUTICS, INC.Exclusive Patent License Agreement • January 4th, 2017 • Signal Genetics, Inc. • Services-medical laboratories • Texas
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (“AGREEMENT”) is between the Board of Regents (“BOARD”) of The University of Texas System (“SYSTEM”), an agency of the State of Texas, on behalf of The University of Texas Southwestern Medical Center at Dallas, whose address is 5323 Harry Hines Boulevard, Dallas, Texas 75390-9094 (“UT SOUTHWESTERN”), a component institution of SYSTEM, and Miragen Therapeutics, Inc. (“LICENSEE”), a Delaware corporation having a principal place of business located at 1900 Ninth Street, Suite 200, Boulder, Colorado 80302.
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “****” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO THE SECURITIES AND...Exclusive Patent License Agreement • July 23rd, 2014 • MetaStat, Inc. • Semiconductors & related devices • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a corporation organized and existing under the laws of the State of Massachusetts, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307, Albert Einstein College of Medicine of Yeshiva University, a Division of Yeshiva University, a corporation organized and existing under the laws of the State of New York, having a place of business at 1300 Morris Park Avenue, Bronx, New York 10461 (“EINSTEIN”), Montefiore Medical Center, a corporation organized and existing under the laws of the State of New York, having an office and place of business at 111 East 210th Street, Bronx, New York 10467 (“MONTEFIORE”) (M.I.T., EINSTEIN, and MONTEFIORE shall be referred to individually and collectively as “THE PARTIES”), and MetaStat BioMedical, Inc., a corporation organized and existing under the laws o
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: 221771 MGII Case No: 21125Exclusive Patent License Agreement • April 24th, 2017 • Biohaven Pharmaceutical Holding Co Ltd. • Pharmaceutical preparations • Massachusetts
This License Agreement (“Agreement”) is made as of the 13 day of September, 2014 (“Effective Date”), by and between BioHaven Pharmaceutical Holding Company, a British Virgin Island corporation, having a principal place of business at Suite 304 / 234 Church Street / New Haven CT 06510 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
University of Minnesota EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • August 11th, 2017 • GT Biopharma, Inc. • Pharmaceutical preparations • Delaware
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
MASSACHUSETTS INSTITUTE OF TECHNOLOGY AND BIND BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 5th, 2013 • BIND Therapeutics, Inc • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and BIND Biosciences, Inc. (“COMPANY”), a Delaware corporation, with a principal place of business at 101 Binney Street, Cambridge, MA 02142.
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • February 14th, 2012 • Atossa Genetics Inc • Surgical & medical instruments & apparatus • Washington
This Exclusive Patent License Agreement is made as of July 27, 2009 (“Effective Date”) between Ensisheim Partners, LLC, a Washington limited liability company (“Licensor”), and Atossa Genetics, Inc., a Delaware corporation (“Atossa”). The parties agree as follows:
EXCLUSIVE PATENT LICENSE AGREEMENT by and between MERCK, SHARP & DOHME CORPORATION and TARGENICS, Inc.Exclusive Patent License Agreement • December 29th, 2017 • ARMO BioSciences, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”), dated as of December 12, 2012 (the “Effective Date”), is by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as “Merck”), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “Licensee”). Merck and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH and RUBIUS THERAPEUTICS, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • June 22nd, 2018 • Rubius Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Agreement, effective as of January 28, 2016, (the “EFFECTIVE DATE”), is by and between the Whitehead Institute for Biomedical Research (“WHITEHEAD”), a Delaware corporation, with a principal office at Nine Cambridge Center, Cambridge, MA 02142, and Rubius Therapeutics, Inc. (“COMPANY”), formerly known as VL26, Inc., a Delaware corporation, with a principal place of business at 620 Memorial Drive, Suite 100 West, Cambridge, MA 02139.
EXCLUSIVE PATENT LICENSE AGREEMENT by and between PURETECH VENTURES LLC and KARUNA PHARMACEUTICALS, INC.Exclusive Patent License Agreement • October 27th, 2020 • PureTech Health PLC • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “Effective Date”), is between PureTech Ventures LLC, a Delaware limited liability company (“PureTech”), and Karuna Pharmaceuticals, Inc., a Delaware corporation (the “Company”). PureTech and the Company are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Amendment 1 EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • March 22nd, 2005 • Tamarack Ventures Inc • Metal mining
Wolfgang Grabher wave his rights from the exclusive patent license agreement, dated as of July 13, 2000 for his rights to receive royalties and agrees to the change of control of Licensee.
exclusive patent LICENSE AGREEMENT (With Comments)Exclusive Patent License Agreement • October 8th, 2020
The framework for the M3 agreement is one in which an R&D institution (university, polytechnic, R&D centre, among others, acting as legal entities) grants a exclusive license to exploit a patent right or a patent pending application to a individual or legal entity of a commercial nature.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. MASSACHUSETTS INSTITUTE OF TECHNOLOGY and A123 Systems, Inc. EXCLUSIVE PATENT LICENSE AGREEMENT Offer to continue negotiations...Exclusive Patent License Agreement • October 31st, 2008 • A123 Systems, Inc. • Miscellaneous electrical machinery, equipment & supplies • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the "EFFECTIVE DATE"), is between the Massachusetts Institute of Technology ("M.I.T."), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and A123 Systems, Inc. ("COMPANY"), a Massachusetts corporation, with a principal place of business at 1 Memorial Drive, 12th Floor, Cambridge, MA 02142.
CONFIDENTIAL TREATMENT REQUESTED UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 15th, 2015 • REGENXBIO Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “EPLA”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
FIRST AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • September 5th, 2018 • Aptorum Group LTD • Pharmaceutical preparations • Hong Kong
THIS FIRST AMENDMENT TO EXCLUSIVE PATENT LICENSE AGREEMENT (the “Amendment”) is made effective as of 7th June, 2018 by and between Versitech Limited, a company incorporated and existing under the laws of Hong Kong with its office at Room 405A, Cyberport 4, 100 Cyberport Road, Hong Kong (the “Licensor”); and Acticule Life Sciences Limited, with incorporation number CB-324541, a company incorporated and existing under the laws of the Cayman Islands, with its registered office at Floor 4, Willow House, Cricket Square, Grand Cayman KY1-9010, Cayman Islands with its management office at Floor 17, Guangdong Investment Tower, 148 Connaught Road, Central, Hong Kong (the “Company”).
VERSITECH LIMITED and ACTICULE LIFE SCIENCES LIMITED EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • April 15th, 2019 • Aptorum Group LTD • Pharmaceutical preparations • Hong Kong
EXCLUSIVE PATENT LICENSE AGREEMENT by and between MERCK, SHARP & DOHME CORPORATION and TARGENICS, Inc.Exclusive Patent License Agreement • April 3rd, 2017 • ARMO BioSciences, Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”), dated as of December 12, 2012 (the “Effective Date”), is by and between Merck, Sharp & Dohme Corporation, a corporation organized and existing under the laws of New Jersey (hereinafter referred to as “Merck”), and Targenics, Inc., a corporation organized and existing under the laws of Delaware (hereinafter referred to as “Licensee”). Merck and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
THE GENERAL HOSPITAL CORPORATION EXCLUSIVE PATENT LICENSE AGREEMENT MGH Agreement No: [***] MGH Case No: MGH [***]Exclusive Patent License Agreement • August 30th, 2021 • HealthCor Catalio Acquisition Corp. • X-ray apparatus & tubes & related irradiation apparatus
This License Agreement (“Agreement”) is made as of the 29th day of May, 2014 (“Effective Date”), by and between Hyperfine Research, Inc., a corporation, having a principal place of business at 530 Old Whitfield Street, Guilford, CT 06437 (“Company”) and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit Massachusetts corporation, with a principal place of business at 55 Fruit Street, Boston, Massachusetts 02114 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • October 6th, 2022 • Colorado
This License Agreement (hereinafter “Agreement”), which shall be effective on the date it is executed by the last Party to sign (the “Effective Date”) below, is between Alliance for Sustainable Energy, LLC (hereinafter "Alliance"), Management and Operating Contractor for the National Renewable Energy Laboratory (hereinafter “NREL”) located at 15013 Denver West Parkway, Golden, Colorado 80401 and [COMPANY NAME], (hereinafter "Licensee"), a for-profit company organized and existing under the laws of the State of [NAME of STATE] and having a principal place of business at [COMPANY ADDRESS], hereinafter referred to individually as “Party” and jointly as “Parties”.
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM AND PELOTON THERAPEUTICS, INC.Exclusive Patent License Agreement • April 26th, 2019 • Peloton Therapeutics, Inc. • Biological products, (no disgnostic substances) • Texas
THIS Agreement (AGREEMENT) is between the Board of Regents (BOARD) of The University of Texas System (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center at Dallas (UT SOUTHWESTERN), a component institution of SYSTEM, and Peloton Therapeutics, Inc. (LICENSEE), a Delaware corporation having a principle place of business located at BioCenter at UT Southwestern Medical District, 2330 Inwood Road, Suite 226, Dallas, Texas 73235-7323.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED. MASSACHUSETTS INSTITUTE OF...Exclusive Patent License Agreement • November 13th, 2020 • Sigilon Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This Agreement, effective as of the date set forth above the signatures of the parties below (the “EFFECTIVE DATE”), is between the Massachusetts Institute of Technology (“M.I.T.”), a Massachusetts corporation, with a principal office at 77 Massachusetts Avenue, Cambridge, MA 02139-4307 and Sigilon, Inc. (“COMPANY”), a Delaware corporation, with a principal place of business at One Memorial Drive, Cambridge, MA 02139.
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM ANDExclusive Patent License Agreement • July 15th, 2009 • Texas
THIS Agreement (AGREEMENT) is between the Board of Regents (BOARD) of The University of Texas System (SYSTEM), an agency of the State of Texas, whose address is 201 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center at Dallas (UT SOUTHWESTERN), a component institution of SYSTEM, and ________________ (LICENSEE), a _____________ corporation having a principal place of business located at _______________.
EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • December 1st, 2020 • Folkup Development Inc. • Retail-miscellaneous retail • Nevada
This Exclusive Patent License Agreement (hereinafter called “Agreement”), entered into and effective as of the 25th day of November, 2020 (hereinafter called “Agreement Date”), is by and between PowerWatt Engineering Co. Ltd., an entity duly formed an existing under the laws of Hong Kong (hereinafter called “Licensor”), and Folkup Development Inc., a Nevada corporation (hereinafter, called “Licensee”).
UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • July 15th, 2020 • Acutus Medical, Inc. • Surgical & medical instruments & apparatus • Delaware
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
Regents of the University of Minnesota and [Insert Name of Licensee] Office for Technology Commercialization OTC Agreement Number: Insert Agreement Number| OTC Case Number : Insert OTC Case NumberExclusive Patent License Agreement • May 5th, 2020
THIS EXCLUSIVE PATENT LICENSE AGREEMENT FOR INDUSTRY SPONOSRED RESEARCH (this “Agreement”) is made as of the Effective Date by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below.
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN ANALOG BIOSCIENCES, INC. AND ARTELO BIOSCIENCES, INC. EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • August 4th, 2017 • Artelo Biosciences, Inc. • Services-business services, nec • California
This exclusive license agreement (“Agreement”) is effective July 3, 2017 (“Effective Date”), by and between (a) Analog Biosciences, Inc. (“Licensor”), a Nevada corporation, having an office at 1340 Specialty Dr., Ste i, Vista, CA 92081, and (b) Artelo Biosciences, Inc. (“Licensee”), a Nevada corporation having a principal place of business at 564 Wedge Lane, Fernley, NV 89408. Licensor and Licensee may be referred to herein, on occasion, individually as “Party” or collectively as “Parties”.
THE BRIGHAM AND WOMEN’S HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: 107605.05 BWH Case Nos: 10706, 11049Exclusive Patent License Agreement • July 18th, 2018 • Aridis Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
This License Agreement (“Agreement”) is made as of the tenth day of November, 2010 (“Effective Date”), by and between Aridis Pharmaceuticals, LLC, a California corporation, having an office at 5941 Optical Court, San Jose, CA 95138 (“Company”) and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • July 3rd, 2017 • Calyxt, Inc. • Agricultural chemicals • Minnesota
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 200 Oak Street, SE, Suite 280, Minneapolis, Minnesota 55455 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA AND CALDERA PHARMACEUTICALS, INC. OFFICIAL USE ONLY May be exempt from public release under the Freedom of Information Act (5 U.S.C. 552), exemption number and...Exclusive Patent License Agreement • June 8th, 2012 • Caldera Pharmaceuticals Inc • Services-commercial physical & biological research • California
UNIVERSITY OF MINNESOTA EXCLUSIVE PATENT LICENSE AGREEMENTExclusive Patent License Agreement • December 29th, 2020 • Cellectis S.A. • Biological products, (no disgnostic substances) • Minnesota
THIS EXCLUSIVE PATENT LICENSE AGREEMENT (this “Agreement”) is made by and between Regents of the University of Minnesota, a constitutional corporation under the laws of the state of Minnesota, having a place of business at 1000 Westgate Drive, Suite 160, St. Paul, Minnesota 55114 (the “University”), and the Licensee identified below. The University and the Licensee agree that:
Second Amendment to Exclusive Patent License Agreement Between University of Arizona and Oncothyreon, Inc. Effective 15 September 2005Exclusive Patent License Agreement • March 14th, 2011 • Oncothyreon Inc. • Services-commercial physical & biological research
This Second Amendment (“Second Amendment”), effective on the date of last authorized signature affixed hereto, is by and between the Arizona Board of Regents on behalf of the University of Arizona, having an office at 888 N. Euclid Avenue, Room 204, Tucson, Arizona 85721 (“LICENSOR”), and Oncothyreon, Inc., having its principal office at 2601 Fourth Avenue, Suite 500, Seattle, Washington 98121 (“LICENSEE”).
THE BRIGHAM AND WOMEN’S HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: [***] BWH Case No: [***], [***], and [***]Exclusive Patent License Agreement • June 25th, 2021 • Candel Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This License Agreement (“Agreement”) is made as of the 15th day of September, 2020 (“Effective Date”), by and between Advantagene, Inc., a Delaware corporation, having a principal place of business at 440 Lexington Avenue, Auburndale, MA 02466 (“Company”) and The Brigham and Women’s Hospital, Inc., a not-for-profit Massachusetts corporation, with a principal place of business at 75 Francis Street, Boston, Massachusetts 02115 (“Hospital”), each referred to herein individually as a “Party” and collectively as the “Parties”.
EXCLUSIVE PATENT LICENSE AGREEMENT BY AND BETWEEN HARRY L. KAUFHOLD, JR. AND MAXXON, INC. This Agreement ("Agreement"), is executed effective April 30, 1997 for the exclusive license of Patent No. 5,125,898 dated June 30, 1992 regarding the Disposable...Exclusive Patent License Agreement • December 23rd, 1999 • Maxxon Inc • Oklahoma
